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httpicense.Abstract Background: Despite progress in life-support measures and antimicrobial therapy, the
mortality of severe pneumonia has not varied since the mid-1990s, suggesting that other factors
are of crucial importance in the evolution of this respiratory infection.
Objective: To evaluate the impact of hydrocortisone infusion in community-acquired pneumonia
(CAP) in the attenuation of systemic inﬂammation and reduction of sepsis-related complications.
Methods: The study enrolled 80 patients, clinically and radiolodically diagnosed as community-
acquired pneumonia, admitted to Chest department, Respiratory Intensive Care Unit, General
Medicine Department and General Medicine Intensive Care Unit of Zagazig University Hospitals.
Sixty of them were randomized to receive hydrocortisone as a bolus dose of 200 mg intravenously
once (only at day 1) then 10 mg/h IV infusion for 7 days and twenty received placebo, along with
antibiotics according to IDSA/ATS 2007 guidelines which were given for both groups. The follow-
ing parameters were compared in both groups; PaO2 and PaO2/FiO2 ratio, length of hospital stay,
duration of IV antibiotic treatment, duration of mechanical ventilation, weaning success from
mechanical ventilation, pneumonia complication and hospital outcome.
Results: Hydrocortisone treated patients showed a signiﬁcant improvement in PaO2 and PaO2/
FiO2 ratio, a signiﬁcant reduction in White blood cell count, C-reactive protein levels, Erythrocyte
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440 R.M. Nafae et al.antibiotic treatment, pneumonia complications, and length of hospital stay. Also there was an
improvement of hospital outcome, weaning success from mechanical ventilation and radiological
resolution compared to the placebo group.
Conclusion: Adjunctive 7 day course of low dose hydrocortisone IV in patients with CAP has-
tens clinical recovery and prevents the development of sepsis-related complications with a signiﬁ-
cant reduction in the duration of mechanical ventilation, duration of IV antibiotics and length of
hospital stay with the improvement in hospital outcome and weaning success from mechanical ven-
tilation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Community-acquired pneumonia (CAP) is one of the 10 leading
causes of death worldwide. Approximately 20% of CAP patients
require hospitalization, 25% of whom are admitted to an inten-
sive care unit (ICU) and have a mortality rate of 30–50% [1]. De-
spite progress in life-support measures and antimicrobial
therapy, the mortality of severe pneumonia has not varied since
the mid-1990s, suggesting that other factors are of crucial impor-
tance in the evolution of this respiratory infection [2].
Antimicrobial treatment has been acknowledged as the cor-
nerstone of the management of patients with community-ac-
quired pneumonia (CAP) [3], Indeed, the case fatality of
untreated bacteremic pneumococcal pneumonia was ini-
tially_80%, while the introduction of antimicrobials led to a
reduction of its associated mortality to 20%. Thus, guidelines
on the management of CAP focus mainly on issues dealing
with the administration of antimicrobial agents (namely, selec-
tion of the most appropriate regimen, timing, dosage, route
and duration of its administration) [4].
Glucocorticoids, the most important natural inhibitors of
inﬂammation, are not always effective in suppressing life-
threatening systemic inﬂammation. The presence of systemic
inﬂammation induced tissue resistance to gluco-corticoids
and/or inadequate adrenal output might explain why older
clinical trials found no efﬁcacy with a time limited course of
massive doses of glucocorticoids [5], while recent randomized
studies have shown efﬁcacy and safety with prolonged gluco-
corticoid treatment in low to moderate doses in patients with
catecholamine-dependent septic shock, severe pneumocystis
pneumonia, and unresolving ARDS [6]. Several studies dem-
onstrated that the infusion of moderate doses of corticoste-
roids could blunt the systemic pro-inﬂammatory cytokine
response in severe sepsis and the pulmonary inﬂammation in
severe pneumonia and acute lung injury [7].
Aim of the work
To evaluate the impact of hydrocortisone infusion in commu-
nity acquired pneumonia(CAP) on clinical recovery and hospi-
tal outcome, and its role in the attenuation of systemic
inﬂammation and reduction of sepsis -related complications.
Patients and methods
The study was conducted on eighty patients with community-
acquired pneumonia (45 males and 35 females), their ages ran-
ged from 18 to 65 years with a mean of (49.01 ± 13.33 years).Patients were admitted to the Chest Department, Respiratory
Intensive Care Unit, General Medicine Department and Gen-
eral Medicine Intensive Care Unit of the Zagazig University
Hospitals, in the period from September 2010 to September
2012.
Patients:
The patients were enrolled in this study according to the fol-
lowing criteria:
Inclusion criteria:
1. Patients with clinical and radiographic evidence of CAP
(pneumonia diagnosed by clinical signs and symptoms:
cough with or without sputum, fever > 38.5, dyspnea,
pleuritic chest pain or abnormal breath sounds, and
radiographic pulmonary abnormalities that are at least
segmental and are not due to preexisting or other known
causes) which was acquired at the community or within
the ﬁrst 48 h of hospitalization according to (Fine et
al.[8]).
2. Age 18 years or older.
 Exclusion criteria:
1– Nosocomial pneumonia or HCAP.
2– Severe immunosuppression (HIV, use of immuno-sup-
pressant such as cytotoxic drugs, Cyclosporins, Mono-
clonal antibodies etc.).
3– Acute burn injury.
4– A preexisting medical condition with life expectancy less
than 3 months (i.e., malignancy).
5– Pregnancy.
6– A major GIT bleeding within 3 months of the current
hospitalization.
7– Acute asthma, chronic obstructive pulmonary disease or
autoimmune disorders (COPD) (i.e., any condition
requiring more than 0.5 mg/kg/day of prednisone
equivalent).
8– Hepatic cirrhosis.
After diagnosis of CAP as described before in the inclusion
criteria, then subgroup analysis of patients according to Pneu-
monia Severity Index (PSI) introduced by Fine et al. [8] was
done. Patients were classiﬁed into mild, moderate and severe
CAP.Treatment Assignments
Each group of mild, moderate and severe CAP patients were
randomly divided into hydrocortisone group (H group) &
Table 1 Demographic and clinical data of patients at study entry.
Parameter Hydrocortisone Placebo t P
Age(mean ± SD) 50.1 ± 13.3 45.8 ± 13.1 1.269 NS
N. % N. % X2 P
Sex 0.8 NS
Male 32 53.3 13 65
Female 28 46.7 7 35
Smoking habit 3.2 NS
Cigg. 23 38.33 5 25
Goza 17 28.33 5 25
Combined 6 10 5 25
Non smokers 14 23.33 5 25
Clinical data
Confusion 9 15% 4 20% 0.276 NS
Mean ± SD Mean ± SD t p
H.R.(b/min) 122.1 ± 11.6 123.7 ± 9.8 0.54 NS
R.R.(/min) 27.18 ± 6.55 28.7 ± 4.3 0.966 NS
Systolic bl.p.(mmHg) 105.8 ± 11.8 101.75 ± 13.8 1.28 NS
Diastolic bl.p (mmHg) 71.2 ± 8.3 70.3 ± 8.8 0.42 NS
Temperature (C) 39 ± 0.7 39.2 ± 0.8 0.669 NS
v2: Chi- square test, P: P-value, N.: Number, t: t test, HR: heart rate,
R.R: respiratory rate, Bl.p: blood pressure, NS: non signiﬁcant, t: t- test,
SD: standard deviation.
Table 2 Laboratory investigations in both hydrocortisone and placebo groups.
Variables Hydrocortisone group (N. 60) Mean ± SD Placebo group (N. 20) Mean ± SD t P
CBC
WBC(·103/cm) 17.8 ± 4.5 17 ± 4.5 0.661 NS
Hct.% 30 ± 4.2 28.9 ± 2.7 1.09 NS
PLT. (·103/cm) 249.56 ± 120.3 300.4 ± 92.8 1.72 NS
BUN mg/dl 31.6 ± 14.2 41.8 ± 19.5 2.156 NS
Creatinine mg/dl 1.14 ± 0.5 1.5 ± 0.8 1.892 NS
CRP mg/l 91.3 ± 39.96 95.4 ± 45.64 0.381 NS
ESR mm/hr 79.9 ± 9.7 81.7 ± 6 0.981 NS
Glucose level mg/dl 195.3 ± 85.1 211.4 ± 94.9 0.674 NS
Electrolyte
Na level mEq/L 131.9 ± 6 130.1 ± 3.71 1.284 NS NS
K level mEq/L 3.6 ± 0.46 3.63 ± 0.44 0.343 NS NS
PaO2/FiO2 ratio 343.9 ± 51.6 319.4 ± 54.3 1.814 NS NS
Cortisol level (ug/ml) 18.38 ± 7.8 22.3 ± 10.2 1.79 NS NS
P: P-value, N.: Number, t: t test, NS: non signiﬁcant, CBC: Complete blood cell count, WBC: White blood cell count, Hct: Hematocrit value,
PLT: Platelet count.
BUN: Blood urea nitrogen, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, Na: sodium level, K: potassium level, t: t test, SD:
standard deviation, PaO2/FiO2: Arterial oxygen tension/Inspired oxygen fraction.
Role of corticosteroids in the treatement of pnemonia role 441placebo or control group (P group) in a 3:1 single – blind man-
ner. Placebo group (20 patients) received sterile normal saline
in a volume equal to the study drug. Hydrocortisone group (60
patients) was given an intravenous 200-mg hydro-cortisone
loading bolus dose followed by an infusion of hydrocortisone
240 mg in 500 cc 0.9% saline at a rate of 10 mg/hour for 7 days
according to Emad Eldin et al. [9].
Initial antibiotic therapy followed the 2007 Infectious
Diseases Society of America/ American Thoracic Society
Consensus Guidelines for the initial management of adults
with community-acquired pneumonia [4], then after that path-
ogen-directed therapy was given.Methods:
Patients who had met the inclusion criteria of this work
were subjected to the following:
1. Thorough medical history taking from patients or their rel-
atives in mechanically ventilated patients.
2. Full clinical examination, including general and local chest
examinations. Detection of improvement was assessed by
comparison of vital signs in day 1 andday 7.
3. Laboratory investigations included: Complete blood count,
Kidney function tests, Liver function tests, Serum sodium
Table 3 Clinical & laboratory data of both hydrocortisone and placebo groups after 7 days of treatment.
Variables Hydrocortisone group Placebo group v2 P
Consciousness N. of improved cases/total number of cases
with impaired conscious level (%)
7/9 (77.8%) 0/4 (0%) 15 <0.001
Mean ± SD Mean ± SD t P
HR(b/min) 105.4 ± 11 113.9 ± 11.8 2.921 <0.05
Systolic Bl.p mmHg 109.92 ± 10.8 102.75 ± 16.5 2.24 <0.05
Diastolic Bl.p mmHg 75 ± 6.64 68.3 ± 11 3.29 <0.05
R.R(/min) 20.7 ± 3.94 27.5 ± 4 –6.71 <0.001
Temperature(C) 37.7 ± 0.6 38.2 ± 0.99 –2.91 <0.05
II. Investigations
CBC:
WBC (x103/cm) 9.2 ± 3.6 11.96 ± 5.5 2.57 <0.05
Hct% 32.6 ± 3.97 31.1 ± 3.79 1.527 NS
Glucose level mg/dl 194.8 ± 105.6 202 ± 85.3 0.307 NS
CRP mg/L 16.3 ± 18.9 43.7 ± 46.2 3.77 <0.001
ESR mm/hr 10.1 ± 12.2 38.7 ± 32.2 5.79 <0.001
Creatinine mg/dl 1.15 ± 0.54 1.7 ± 0.96 1.156 NS
BUN mg/dl 28.95 ± 12.99 42.8 ± 17.82 2.892 NS
Electrolyte
Na mEq/l 138.1 ± 2.4 134.6 ± 4.7 4.37 <0.00
K mE/l 3.37 ± 0.4 3.6 ± 0.4 2.73 <0.05
Cortisol level (lg/ml) 21.7 ± 7.3 24.6 ± 10.2 1.38 NS
PaO2/FiO2 ratio 365.5 ± 61.4 321.5 ± 101.9 2.32 <0.05
N.: Number, t: t-test, v2: Chi- square test, HR: heart rate, RR: respiratory rate.Bl.p: blood pressure, WBC: White blood cell count, Hct:
Hematocrit value.CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, Na: sodium level,K: potassium level, PaO2/FiO2: Arterial
oxygen tension/inspired oxygen fraction.
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tion rate, C-reactive protein (CRP) and SerumCortisol level.
4. Radiological investigations included: Plain Chest X- ray on
day 1, 4 and day 7, Chest Computed Tomography (C.T)
that was done for non responding patients to conﬁrm the
diagnosis of pneumonia and direct CT guided biopsy. Chest
Ultrasonography (U.S) was done for all cases to conﬁrm or
exclude the presence of parapneumonic pleural effusion.
5. Bacteriological investigations included: Gram stain of spu-
tum and pleural ﬂuid, sputum culture and sensitivity, Blood
culture, pleural ﬂuid culture &sensitivity, Quantitative cul-
ture of C.T guided biopsy, Quantitative culture and gram
stain of tracheobronchial secretions obtained by tracheal
aspirate in intubated patients and bronchoscopic BAL
and mini BAL in non intubated patients.
Statistical analysis
All data were collected, tabulated and reformed for statistical
analysis using Statistical Package for Social Science (SPSS ver-
sion 19; SPSS, Inc., Chicago, IL). The results of this work were
analyzed and presented as numbers and percentage or
mean ± standard deviation(SD). Student’s ‘‘t’’ test, analysis
of variance (ANOVA) and Chi-square (v2 test or Fisher’s ex-
act test) were used for comparison between groups. A P-value
<0.05 was considered signiﬁcant and P-value <0.001 was
considered highly signiﬁcant .
Results
After analysis of data from 80 patients (60 CAP patients in
hydrocortisone group and 20 CAP patients in placebo group),demographic and clinical data of patients did not differ be-
tween the two groups (Table 1), this means that the two groups
were matched.
Table 2 shows that the laboratory investigations that were
done to both groups (hydrocortisone and placebo) (CBC,
BUN, Creatinine, CRP, ESR, glucose level, Na, K, PaO2/
FiO2 ratio and cortisol level) at the study entry were also
matched.
Table 3 shows the follow up of clinical and laboratory data
of patients of both group after 7 days, which proved that there
were a non signiﬁcant difference between both hydrocortisone
and placebo groups in the improvement of Creatinine, BUN,
cortisol level, Hct value and glucose level. As regards improve-
ment of clinical data in the hydrocortisone versus placebo
group, there was a statistically signiﬁcant improvement in
the hydrocortisone group regarding: conscious level, mean
heart rate, mean respiratory rate, mean systolic blood pressure,
mean diastolic blood pressure and mean temperature readings.
As regards other laboratory investigations: WBC, CRP, ESR,
Na level, K level and PaO2/FiO2 ratio, there was a statistically
signiﬁcant improvement in the hydrocortisone group except
for the serum K level.
As regards complications that occurred during the study in
both CAP groups (Table 4); less pneumonia complications
(septic shock or ARDS) occurred in the hydrocortisone versus
placebo groups (6.7% vs 30%), complications of steroids dur-
ing the study were statistically non signiﬁcant between both
groups except hypokalemia which was more in the hydrocorti-
sone group versus placebo group (58.3% vs 25%) and this was
a correctable side effect.
As regards mechanical ventilation of severe CAP patients in
both groups (Table 5); there was a non signiﬁcant difference
between both groups in the need for mechanical ventilation
Table 5 Need, duration and weaning success of mechanical ventilation of severe CAP patients in both groups.
Variables Hydrocortisone group (N. 60) Placebo group (N. 20) v2 P
N. % N. %
Need for mechanical ventilation 8 13.3 5 25 1.5 NS
Weaning success 7 87.5 1 20 0.74 <0.05
t P
Duration of mechanical ventilation range 5–24 days 12–22 days 2.375 <0.05
Mean ± SD 1.2 ± 3.75 days 4.3 ± 7.83 days
v2: Chi-square test, N.: Number, NS: non signiﬁcant, P: P-value, SD: standard deviation, t: t-test.
Table 6 Duration of IV antibiotics, radiological resolution, and LOS and hospital outcome after 7 days in both groups of CAP.
Variables Hydrocortisone group (N. 60) Placebo group (N. 20) v2 P
N. % N. %
CXR improvement 56 93.3 14 70 7.5 <0.05
Hospital outcome
No. Of Improved Cases 56 93.3 13 68.4 8.1 <0.05
No. Of Deaths 4 6.7 6 31.6 7.83 <0.05
Mean ± SD Mean ± SD t P
LOS
In ICU 3.1 ± 4.9 6.3 ± 8.2 2.124 <0.05
In Ward 6.2 ± 3.7 0.2 ± 7.8 –3.09 <0.05
Total hospital stay 9.27 ± 2.4 16.5 ± 2.24 –11.8 <0.05
Duration of IV AB 7.45 ± 2.6 13.9 ± 2.98 9.223 <0.001
v2: Chi- square test, P: P-value, N.: Number, t: t-test, SD: standard deviation.
CXR: Chest x ray, LOS: length of hospital stay, ICU: intensive care unit.
IV: intravenous, AB: antibiotic, MV: mechanical ventilation.
Table 4 Complications that occurred during the study in both CAP groups.
Variables Hydrocortisone group (N. 60) Placebo group (N. 20) v2 P
N. % N. %
Pneumonia complications (Septic shock or ARDS) 4 6.7 6 30 7.4 <0.05
Drug complications
*GIT bleeding 1 1.6 1 5 8.6 NS
*hypokalemia 35 58.3 5 25 7.3 <0.05
*Uncontrolled DM (glucose > 250 mg/dl) 19 31.7 8 40 8.5 NS
v2: Chi-square test, N.: Number, NS: non signiﬁcant, P: P-value, SD: standard deviation, t: t-test.
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the hydrocortisone group than the placebo group was ob-
served (87.5% vs 20%). The duration of mechanical ventila-
tion ranged from 5–24 days with a mean of (1.2 ± 3.75 days)
in the hydrocortisone group versus 12–22 days with a mean
of (4.3 ± 7.83 days) in the placebo group.
Table 6 shows duration of IV antibiotics, radiological reso-
lution, length of hospital stay and hospital outcome after
7 days in both groups; CXR clearance was signiﬁcantly more
frequent in the hydrocortisone group versus the placebo group,
hospital outcome showed a statistically signiﬁcantly greater
number of improved cases and lesser number of deaths
(6.7% vs 31.6%)in the hydrocortisone group, Total length of
hospital stay and duration of IV antibiotics were less in the
hydrocortisone group and the difference was statistically
signiﬁcant.Discussion
Despite steady improvement in antibiotic therapy and inten-
sive care management during the past decade, mortality from
severe community-acquired pneumonia has remained high; a
fact that has continued to stimulate interest in pharmacologi-
cal agents that might reduce morbidity and mortality. It has
been recently hypothesized that hydrocortisone administration
initiated early in the course of severe CAP alters pulmonary
and systemic responses and leads to earlier resolution of pneu-
monia and a reduction in sepsis-related complications and
mortality [10].
In this study and after 7 days follow up of both hydrocorti-
sone and placebo groups, pneumonia complications (septic
shock, ARDS); were less in the hydrocortisone group when
compared with the placebo. As regards the most common side
444 R.M. Nafae et al.effects that occur with steroid therapy, there was non signiﬁcant
difference in both GIT bleeding and uncontrolled diabetes mel-
litus, while there was a signiﬁcant difference in hypokalemia
which was more in the hydrocortisone group (58.3%) (Table
4) which was a correctable side effect and this was attributed
to the mineralocorticoid action of hydrocortisone. So this study
conﬁrmed that the use of hydrocortisone in a low dose for a
short period had a protective effect against pneumonia compli-
cations with less steroid side effects. This was in agreement with
Confalonieri et al. [10], Rhen & Cidlowski [12] and Emad Eldin
et al. [9] while Meduri and colleagues [13] found no effect of
methylprednisolone infusion in decreasing pneumonia compli-
cations, in contrast there was an increase in the occurrence of
delayed septic shock in the steroid group. Corticosteroids are
very potent inhibitors of inﬂammation [12]. They switch off
genes that encode proinﬂammatory cytokines and switch on
genes that encode anti-inﬂammatory cytokines. Treatment with
low dose corticosteroids down regulates proinﬂammatory
cytokine transcription, which prevents an extended cytokine re-
sponse and might accelerate the resolution of systemic and pul-
monary inﬂammation in the early phase of community-
acquired pneumonia [15]. In this study, there was a non signif-
icant difference in the need of mechanical ventilation in both
hydrocortisone and placebo groups (matching in both groups),
while there was a signiﬁcant difference between weaning success
which was more in the hydrocortisone group (87.5%) than the
placebo group (20%). Regarding the duration of mechanical
ventilation, the mean duration of mechanical ventilation
was signiﬁcantly shorter in the hydrocortisone group
(1.2 ± 3.75 days) in comparison to the placebo group
(4.3 ± 7.83 days) (Table 5). This is in agreement with Confalo-
nieri et al. [10], El-Ghamrawy et al. [11], Emad-Eldin Omar et
al. [9] and Meijvis et al. [15] who postulated that adjunctive
treatment of community acquired pneumonia with intravenous
dexamethasone changed the immune response and reduced
morbidity, leading to a decrease in patients’ length of stay in
hospital. They illustrated that dexamethasone has potent
anti-inﬂammatory effects and weak mineralocorticoid effects
compared with other corticosteroids, thus avoiding interference
with sodium reabsorption and water balance. Moreover, dexa-
methasone has a long-lasting effect, allowing for once-a-day
regimen. In this study and as regards the clinical and laboratory
variables of the follow up that was done at the 7th day of the
study; there were highly signiﬁcant differences in the improve-
ment of conscious level, CRP, ESR, Na level, RR (P< 0.001)
which improved more in the hydrocortisone group .The obser-
vation of a more reduction of CRP in the hydrocortisone group
after the course of therapy is in agreement with the result re-
ported by Confalonieri et al. [10] and Meijvis et al. [15]. CRP
has been effectively used as a marker for pulmonary and sys-
temic inﬂammation. Cortico-steroids could reduce the exagger-
ated inﬂammatory response in severe infection. In the present
study there was signiﬁcant difference in the improvement of:
HR, Bl.p, temperature, WBCs count & PaO2/FiO2 ratio which
improved more in the hydro-cortisone group. This ﬁnding that
the hydrocortisone group showed more improvement in pul-
monary oxygenation parameters following the treatment
course as compared with placebo group, is in accordance with
that of El-Ghamrawy et al. [11] who reported that patients ran-
domized to a 7-day hydro-cortisone infusion had a signiﬁcant
improvement in PaO2/FiO2. In this study, there was nonsigniﬁcant difference in blood glucose level, serum cortisol level
and Hct value in both hydrocortisone and placebo groups (Ta-
ble 3). As regards other improvement parameters, there was a
signiﬁcant difference in CXR resolution, pneumonia and drug
complications, both ICU and ward length of stay and hospital
outcome (number of deaths and number of improved cases) in
both the hydrocortisone and the placebo groups (as the
improvement was more in the hydrocortisone group), also there
was a highly signiﬁcant difference (P< 0.001) in the total
length of stay and duration of mechanical ventilation in both
groups (being less in the hydro-cortisone group) (Table 6).
These results are in agreement with other studies that suggested
that patients with severe community-acquired pneumonia who
were treated with systemic cortico-steroids had a reduced risk
of mortality compared with patients who were not given
adjunctive corticosteroids [10,16,15]. They also hypothesized
that if these potential beneﬁts of such relatively cheap treatment
proved, this would decrease economic and social burdens and
allow for better allocation of hospital resources; while Salluh
et al. [17] showed that corticosteroids did not improve hospital
mortality rates or survival, also Polverino et al. [18] studied pa-
tients with community-acquired pneumonia of any severity and
compared prednisolone for 3 days with the placebo and re-
ported a non-signiﬁcant reduction in hospital stay from 16 to
11 days (p= 0Æ182). However, this study used a shorter dura-
tion of steroid therapy and this could explain their poor results.
Also the study of Mikami et al. [14] who assessed the role of
prednisolone (40 mg once per day for 7 days) in community-ac-
quired pneumonia of any severity showed neither beneﬁcial ef-
fects of adjunctive corticosteroids on clinical cure at day 7 or
effects on the length of stay. A possible explanation for the ab-
sence of effects compared with our study was the use of prednis-
olone once a day, which might not have been sufﬁcient to
achieve effective serum concentrations during the course of
24 h. Furthermore, this study was not powered to show differ-
ences in the length of hospital stay.
In conclusion: adjunctive 7 day course of low dose hydro-
cortisone IV in patients with CAP fastens recovery and pre-
vents the development of sepsis-related complications with a
signiﬁcant reduction in the duration of mechanical ventilation,
duration of IV antibiotic treatment and length of hospital stay
with improvement of hospital outcome and weaning success
from mechanical ventilation.References
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